ArticleHIV medicine2018
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.
Article in HIV medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Pooled it
- Advancements in development of novel class of HIV protease inhibitors.Annals of medicine · 2026Review
- Drug Resistance Assessment of Commonly Used Anthelmintics, and Their Combination Effect in Naturally Infected Sheep: The Case of Kaffa Zone, Southwestern Ethiopia.Veterinary medicine and science · 2026Article
- Analysis of HIV Drug Resistance Mutations Along With Treatment Outcomes of Efavirenz-Based Regimens in Patients With V179D/E Mutations in Guangzhou, China.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Risk factors for virologic failure and persistent low-level viremia in people with HIV experiencing low-level viremia: Chongqing ART cohort study, 2019-2023.Frontiers in medicine · 2025Article
- Cytokines assets in PLWH in two-drug dolutergravir based or three-drug antiretroviral regimen.BMC infectious diseases · 2024Article
- Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.Journal of virus eradication · 2023Review
- Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review.Transplantation direct · 2023Article
- Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023Review
- Article
- Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples.Annals of laboratory medicine · 2022Article
- Changing demographics and immunity to vaccine preventable diseases in people with HIV in Ireland.BMC infectious diseases · 2022Article
- Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea.Scientific reports · 2022Article
- Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China.Infection and drug resistance · 2021Article
- NASH in HIV.Current HIV/AIDS reports · 2020Review
- Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?Open forum infectious diseases · 2020Review
- Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients.Infection & chemotherapy · 2020Article
- Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population.Liver international : official journal of the International Association for the Study of the Liver · 2020Article
- HIV and cardiovascular disease.The lancet. HIV · 2020Review
- Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.BMC infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. GUIDELINE HIGHLIGHTS: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug-drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months.
conclusionsVersion 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.